News

Paul G Richardson, MD, and colleagues presented a study at the 64th ASH Annual Meeting and Exposition and discussed updated and longer-term efficacy data regarding multiple lines of therapy subsequent to ICARIA-MM.

Mitchell R Smith, MD, and colleagues presented data at the 64th ASH Annual Meeting and Exposition on whether progression-free survival is prolonged by the addition of bortezomib to bendamustine-rituximab induction and/or by the addition of...

Speaking at the 64th ASH Annual Meeting and Exposition, Fumou Sun, PhD, and colleagues discussed a 12-gene score that demonstrated noticeable accuracy in predicting 10-year progression to multiple myeloma in a limited population of patients...

Julie Cote, MD, and colleagues discuss real-world outcomes of patients treated with autologous stem cell transplant as part of their initial multiple myeloma therapy during their presentation at the 64th ASH Annual Meeting and Exposition.

Momelotinib improved symptom responses, transfusion requirements, and spleen responses for symptomatic and anemic myelofibrosis patients previously treated with a JAK inhibitor when compared with danazol, according to the phase 3 MOMENTUM...

Renal cell carcinoma (RCC) recurrence is correlated with a significant increase in mortality, health care resource utilization (HRU), and health care costs, emphasizing the substantial unmet need in patients with intermediate high-risk and...

Findings from a recently published study reveal that participation in the Oncology Care Model (OCM) did not dissuade oncologists from prescribing expensive, novel therapies to Medicare beneficiaries with cancer.

Momelotinib was superior to danazol in symptomatic, anemic, and thrombocytopenic myelofibrosis patients for symptom responses, transfusion requirements, and spleen responses, according to a phase 3 trial.

A recent study found that second-line chemotherapy among patients with NSCLC complicated by interstitial lung disease (ILD) has a certain effectiveness, but some patients may experience harsh adverse effects of ILD.

Immunoglobulin G (IgG) class-switched mutated chronic lymphocytic leukemia (M-CLL) likely represents the same disease as IgM M-CLL rather than a different biological and/or clinical entity, according to a recent study.